Doxorubicin free base | Adriamycin | CAS#CAS#23214-92-8

MedKoo Cat#: 100960 | Name: Doxorubicin free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Doxorubicin free base, also called doxorubicin, is an anthracycline antibiotic with antineoplastic activity. Approved API for cancer therapeutic use is doxorubicin HCl. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Note: Doxorubicin free base has low solubility in common solvents. The MedKoo original CAT# for this product was 100280a.

Chemical Structure

Doxorubicin free base

CAS#23214-92-8 (free base)

Theoretical Analysis

MedKoo Cat#: 100960

Name: Doxorubicin free base

CAS#: 23214-92-8 (free base)

Chemical Formula: C27H29NO11

Exact Mass: 543.1741

Molecular Weight: 543.52

Elemental Analysis: C, 59.66; H, 5.38; N, 2.58; O, 32.38.

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,250.00	Ready to ship
500mg	USD 2,650.00	Ready to ship
1g	USD 3,850.00	Ready to Ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

23214-92-8 (free base) 25316-40-9 (HCl)

Synonym

ADR; chloridrato de doxorrubicina. Adriamycin; Adriacin; Adriblastina; Adriblastine; Adrimedac; DOXOCELL; Doxolem; Doxorubin; Farmiblastina; Rubex. Abbreviations: ADM; Adria; DOX. Code name: FI106;

IUPAC/Chemical Name

(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione.

InChi Key

AOJJSUZBOXZQNB-TZSSRYMLSA-N

InChi Code

InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1

SMILES Code

O=C1C2=C(O)C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)=C3C(O)=C2C(C5=C1C=CC=C5OC)=O

Appearance

Deep-red to black solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

This product has low solubility in all common solvents.

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO at low concentration.

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

The original CAT# for this product was 100280a.

Certificate of Analysis

View CoA: current batch, Lot#ZY70410

View CoA: current batch, Lot#ZY210816

QC Data

View QC data: current batch, Lot#ZY210816

View QC data: current batch, Lot#ZY70410

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	This product has low solubility in all common solvents.	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 543.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014 Oct-Dec;10(4):853-8. doi: 10.4103/0973-1482.139267. PMID: 25579518. 2: Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988 Jul;15(1):15-31. doi: 10.2165/00003088-198815010-00002. PMID: 3042244. 3: Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267-85. doi: 10.2174/092986709788803312. Epub 2009 Sep 1. PMID: 19548866. 4: Zhu L, Lin M. The Synthesis of Nano-Doxorubicin and its Anticancer Effect. Anticancer Agents Med Chem. 2021;21(18):2466-2477. doi: 10.2174/1871520621666201229115612. PMID: 33372884. 5: Peter S, Alven S, Maseko RB, Aderibigbe BA. Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review. Molecules. 2022 Jul 13;27(14):4478. doi: 10.3390/molecules27144478. PMID: 35889350; PMCID: PMC9318127. 6: Sun Z, Zhou D, Yang J, Zhang D. Doxorubicin promotes breast cancer cell migration and invasion via DCAF13. FEBS Open Bio. 2022 Jan;12(1):221-230. doi: 10.1002/2211-5463.13330. Epub 2021 Dec 5. PMID: 34775691; PMCID: PMC8727929. 7: Meredith AM, Dass CR. Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol. 2016 Jun;68(6):729-41. doi: 10.1111/jphp.12539. Epub 2016 Mar 14. PMID: 26989862. 8: Almajidi YQ, Kadhim MM, Alsaikhan F, Turki Jalil A, Hassan Sayyid N, Alexis Ramírez-Coronel A, Hassan Jawhar Z, Gupta J, Nabavi N, Yu W, Ertas YN. Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. Environ Res. 2023 Jun 15;227:115722. doi: 10.1016/j.envres.2023.115722. Epub 2023 Mar 21. PMID: 36948284. 9: Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target. 1996;4(3):129-40. doi: 10.3109/10611869609015970. PMID: 8959485. 10: Armstrong J, Dass CR. Doxorubicin Action on Mitochondria: Relevance to Osteosarcoma Therapy? Curr Drug Targets. 2018;19(5):432-438. doi: 10.2174/1389450116666150416115852. PMID: 25882220. 11: Schulmeister L. Doxorubicin. Clin J Oncol Nurs. 1998 Jul;2(3):115-6. PMID: 10232157. 12: Alam Khan S, Jawaid Akhtar M. Structural modification and strategies for the enhanced doxorubicin drug delivery. Bioorg Chem. 2022 Mar;120:105599. doi: 10.1016/j.bioorg.2022.105599. Epub 2022 Jan 7. PMID: 35030480. 13: Tan ML, Choong PF, Dass CR. Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol. 2009 Feb;61(2):131-42. doi: 10.1211/jpp/61.02.0001. PMID: 19178759. 14: Chlebowski RT. Adriamycin (doxorubicin) cardiotoxicity: a review. West J Med. 1979 Nov;131(5):364-8. PMID: 394479; PMCID: PMC1271861. 15: Lum BL, Svec JM, Torti FM. Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity. Drug Intell Clin Pharm. 1985 Apr;19(4):259-64. doi: 10.1177/106002808501900403. PMID: 3891276. 16: Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989 May;25(5):873-82. doi: 10.1016/0277-5379(89)90135-1. PMID: 2661240. 17: Cuono CB. Doxorubicin-induced extravasation necrosis. J Hand Surg Am. 1983 Jul;8(4):497-8. doi: 10.1016/s0363-5023(83)80216-0. PMID: 6886347. 18: Alawak M, Dayyih AA, Awak I, Gutberlet B, Engelhardt K, Bakowsky U. Magnetic Thermosensitive Liposomes Loaded with Doxorubicin. Methods Mol Biol. 2023;2622:103-119. doi: 10.1007/978-1-0716-2954-3_9. PMID: 36781754. 19: Tian Z, Yang Y, Yang Y, Zhang F, Li P, Wang J, Yang J, Zhang P, Yao W, Wang X. High cumulative doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer. 2020 Nov 23;20(1):1139. doi: 10.1186/s12885-020-07663-x. PMID: 33228579; PMCID: PMC7684756. 20: Gong J, Yan J, Forscher C, Hendifar A. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. Drug Des Devel Ther. 2018 Apr 6;12:777-786. doi: 10.2147/DDDT.S140638. PMID: 29670334; PMCID: PMC5896668.

1. Wei G, Wang Y, Yang G, Wang Y, Ju R. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics. 2021 Apr 19;11(13):6370-6392. doi: 10.7150/thno.57828. PMID: 33995663; PMCID: PMC8120226.

2. Wei J, Yin L, Li J, Wang J, Pu T, Duan P, Lin TP, Gao AC, Wu BJ. Bidirectional Cross-talk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer. Cancer Res. 2021 Aug 15;81(16):4275-4289. doi: 10.1158/0008-5472.CAN-21-0198. Epub 2021 Jun 24. PMID: 34167949; PMCID: PMC8373824.

3. Saifutiarova AE, Fedorov YV, Tsvetkov VB, Rustamova DA, Gulakova EN, Chmelyuk NS, Abakumov MA, Aliev TM, Fedorova OA. Photochemical synthesis, intercalation with DNA and antitumor evaluation in vitro of benzo[d]thiazolo[3,2-a]quinolin-10-ium derivatives. Bioorg Chem. 2021 Oct;115:105267. doi: 10.1016/j.bioorg.2021.105267. Epub 2021 Aug 16. PMID: 34426158.

4, Baek MJ, Nguyen DT, Kim D, Yoo SY, Lee SM, Lee JY, Kim DD. Tailoring renal-clearable zwitterionic cyclodextrin for colorectal cancer-selective drug delivery. Nat Nanotechnol. 2023 Aug;18(8):945-956. doi: 10.1038/s41565-023-01381-8. Epub 2023 Apr 27. PMID: 37106052.

5. Czupiel P, Delplace V, Shoichet M. Nanoparticle delivery of a pH-sensitive prodrug of doxorubicin and a mitochondrial targeting VES-H8R8 synergistically kill multi-drug resistant breast cancer cells. Sci Rep. 2020 May 26;10(1):8726. doi: 10.1038/s41598-020-65450-x. PMID: 32457422; PMCID: PMC7251113.